About this trial
Introduction:
Endovascular thrombectomy (EVT) is an effective treatment strategy to mitigate the ischemic tissue damage caused by the acute cerebral large-vessel occlusion. However, in clinical practice, nearly half of the patients do not experience adequate neurological improvement despite successful recanalization - a phenomenon termed reperfusion failure or clinically ineffective reperfusion. Given the clinical relevance of this phenomenon and the absence of a standardized imaging diagnostic method to identify it, our project aims to explore the potential role of blood oxygenation-level dependent cerebrovascular reactivity (BOLD-CVR) as novel imaging biomarker for studying reperfusion failure.
Study population:
Adult patients with acute ischemic stroke of the ICA, MCA or with tandem occlusion who have undergone a successful recanalization, described as mTICI score ≥2b.
Objective(s):
Primary objective: to longitudinally observe blood flow changes derived from BOLD-CVR imaging following successful endovascular thrombectomy in patients with large-vessel occlusion acute ischemic stroke (LVO-AIS) during the early post-treatment phase and assess their association with clinical outcome 90 days post-EVT.
Secondary objective: to compare BOLD-CVR findings with those obtained from the clinical standard dynamic susceptibility contrast (DSC) MR perfusion imaging acquired in the same examination session as well as other imaging techniques included in the standard post-treatment imaging protocol at our institution.
Outcomes:
Clinical outcomes:
* 90-day functional outcome. * Functional outcome at hospital discharge. * Neurological deterioration during hospitalization. * Radiologically confirmed haemorrhagic transformation within the reperfused tissue. * Radiologically confirmed infarct lesion progression within the reperfused tissue. * Additionally, DSC MR perfusion imaging parameters and other standard hemodynamic imaging parameters will be considered as imaging outcomes
Study design:
Single-center prospective observational cohort study
Measurements and procedures:
Included patients will undergo a total of 3 BOLD-CVR examinations: 72 hours, 7 days, and 90 days after EVT. Participation in the final examination will mark the end of the subject's involvement in the study. Clinical outcomes will be prospectively collected as per established institutional patient management protocols: during hospitalization, at discharge, and at the cerebrovascular outpatient clinic at 3 months.
Number of Participants:
Target sample size: 100 patients
Given the observational study design and exploratory nature of this project, no sample size calculation can be performed. The provided target sample size (N = 100) has been estimated considering the inclusion of as many consecutive subjects as possible.
Study period: 2.5 years The investigators aim to enroll a target sample size of 100 patients over a period of 2.5 years. This translates to an inclusion of 3-4 patients per month, with the last three months allocated for the follow-up of the last included patients.
Study Centre:
Clinical Neuroscience Center, Department of Neurosurgery, University Hospital Zurich
Statistical Considerations:
The association between BOLD-CVR findings and clinical outcomes will be investigated using regression analyses.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Male and female subjects >18 years old.
Acute ischemic stroke related to a new occlusion of the internal carotid artery, middle cerebral artery (M1- and/or M2-segment), or both.
Eligibility and performance of endovascular thrombectomy.
Achievement of successful recanalization, defined as mTICI score ≥2b
Disqualifiers
Documented evidence or a confirmed willingness of the patient not to participate in any scientific study.
Standard contraindications for MRI, such as pacemaker, metallic prothesis, glaucoma, metallic tattoo dyes, verbal confirmed pregnancy. Unwilling or unable to cooperate with breathing manoeuvres.
Major cardiopulmonary diseases, such as severe uncontrolled asthma bronchiale, severe chronic obstructive lung disease (i.e., GOLD stage ≥III), diffuse interstitial lung disease, pulmonary embolism, acute/subacute myocardial infarction, or severe heart failure (i.e., NYHA class ≥III).
Symptomatic increased intracranial pressure.
Trial population
Patients with an acute ischemic stroke of the ICA, MCA or with tandem occlusion who have had a successful recanalization, defined as mTICI score ≥2b and with written informed consent of the patient or a family member
Trial design
Cohort
Prospective
Treatments tested in this trial
No planned intervention
Other interventionNo planned intervention
Treatment groups
Trial outcomes
Primary outcomes
Comparison of the BOLD-CVR signal with the functional outcome at 3 months
Following a published pipeline, BOLD-CVR values per voxel are obtained through a voxel-wise linear regression analysis between the end-tidal CO₂ time course and the BOLD fMRI signal time course. BOLD-CVR is expressed as the percent BOLD signal change per mmHg CO₂ (%BOLD signal change/mmHg CO₂).9 Predefined anatomical brain masks are applied to delineate three regions of interest: the whole brain, the ipsilateral hemisphere, and the territory of the middle cerebral artery (MCA). These masks are overlaid on the BOLD-CVR maps, and the average BOLD-CVR value is calculated for each region, resulting in average BOLD-CVR values for the whole brain, the ipsilateral hemisphere, and the MCA territory. The functional outcome at 90 days post-EVT will be assessed with the mRS score.
Secondary outcomes
Comparison of the BOLD-CVR signal with the dynamic susceptibility contrast (DSC) MR perfusion imaging signal parameters
Comparison of the BOLD-CVR Signal with the Quantitative Digital Subtraction Angiography signs
Comparison of the BOLD CVR signal with the National Institutes of Health Stroke Scale (NIHSS)
Comparison of the BOLD-CVR signal with the Modified Rankin Scale (MRS)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.